Comparison of efficacy between high NLR and low NLR groups
A total of 127 treated metastatic advanced colorectal cancer patients
were enrolled in this study, among which 65 patients received immune
checkpoint inhibitor therapy. Peripheral blood of 65 patients was tested
within one week before receiving immune checkpoint inhibitor therapy,
and NLR was defined as the ratio of the neutrophil count to the
lymphocyte count of the peripheral blood, and NLR <3 was
classified as the low NLR group; NLR ≥3 was classified as the high NLR
group. The results showed that of the 24 patients in the high NLR group,
13 patients with PD, 10 patients with SD, 1 patient with PR, 1 patient
met the criteria for objective response, and 11 patients met the
criteria for disease control, while of the 41 patients in the low NLR
group, 8 patients with PD, 30 patients with SD, 3 patients with PR, 3
patients met the criteria for objective response, and 33 patients met
the criteria for disease control. The results of different evaluations
of the two groups of patients were statistically analysed separately,
and the results using the Chi-square test and Fisher’s exact test were
as follows: in the case of PD or not, there was a statistical difference
between the two groups, P =0.004; in the case of SD or not, there
was a statistical difference between the two groups, P =0.012; in
the case of PR or not, there was no statistical difference between the
two groups, P =0.610; in the case of objective response or not,
there is no statistical difference between the two groups,P =0.610; in the case of disease control or not, there is a
statistical difference between the two groups, P =0.004, as shown
in Table 4. In summary, among patients with advanced colorectal cancer
treated with immune checkpoint inhibitors, there were statistically
significant differences between patients in the high NLR group and those
in the low NLR group with respect to PD, SD, and disease control. The
NLR level is associated with the efficacy of treatment with immune
checkpoint inhibitors in patients with treated metastatic advanced
colorectal cancer.
Table 4 Comparison of efficacy between high NLR and low NLR
groups